Prasterone

Kocis, Paul T

doi:10.2146/ajhp060100

Cited by 7 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been granted an orphan drug status by the FDA (prasterone) for preservation of bone mineral density in lupus patients receiving glucocorticoids. 33 …”

Section: Discussion Point 9: the Use Of Dhea And Testosterone Therapymentioning

confidence: 99%

See 1 more Smart Citation

Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians

Sood¹,

Shuster²,

Smith³

et al. 2011

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Bioidentical hormones are compounds that have exactly the same chemical and molecular structure as endogenous human hormones. In contrast, nonbioidentical, or synthetic, hormones are structurally dissimilar from endogenous hormones. Although available for years, bioidentical compounded hormone therapy (BCHT) has gained popularity in the United States only recently. This popularity has paralleled women’s rising fears of conventional hormone therapy, especially since the publication of the Women’s Health Initiative clinical trials. Although BCHT offers advantages, it is not the panacea of hormone therapy. The claims that BCHT lowers the risk of breast cancer, coronary artery disease, stroke, or thromboembolism are not supported by scientific research. The goal of this review is to present an overview of the available research evidence on BCHT, dispel myths about the use of compounded hormones, and provide helpful tips to answer commonly asked questions about BCHT.

show abstract

“…It has been granted an orphan drug status by the FDA (prasterone) for preservation of bone mineral density in lupus patients receiving glucocorticoids. 33 …”

Section: Discussion Point 9: the Use Of Dhea And Testosterone Therapymentioning

confidence: 99%

“…33 Elevated endogenous DHEA sulfate levels are associated with an increased risk of breast cancer. 38 …”

Section: Discussion Point 9: the Use Of Dhea And Testosterone Therapymentioning

confidence: 99%

Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians

Sood¹,

Shuster²,

Smith³

et al. 2011

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

show abstract

“…Other declared AAS included: 25R spirostan‐5A‐diol‐6‐one‐3‐one (three products, always in association with DHEA), methandrostenol (2), cyclostanozol (2), 3‐undecanodrol (1), prasterone (1), nandeconate (1), and oxantrione (1). None of these compounds could be identified as existing molecules, with the partial exception of 25R spirostan‐5A‐diol‐6‐one‐3‐one, which might stand for 5‐α, 25R 5‐hydroxy‐spirostan‐3,6‐dione (Dawidar et al, 1980), and of prasterone, which might indicate the proprietary name of a DHEA‐containing product (Kocis, 2006). Methandrostenol might stand for methandrostenolone; however, the content declared (230 mg/capsule) would be exceedingly high for this compound.…”

Section: Resultsmentioning

confidence: 99%

“…3‐undecanodrol (in some way resembling nandrolone decanoate), cyclostanozol (stanozolol), nandeconate (again, nandrolone decanoate), oxantrione (oxandrolone). Prasterone resembles the proprietary name of a DHEA‐containing medicinal (Kocis, 2006), another possible strategy to deceive purchasers. Another indirect evidence, in particular for AAS‐containing products sold as medicines, that they might not necessarily contain the compound and/or the amount declared comes from comparison of selling prices with those of corresponding medicines.…”

Section: Discussionmentioning

confidence: 99%

Selling androgenic anabolic steroids by the pound: identification and analysis of popular websites on the Internet

Cordaro

Lombardo

Cosentino

2011

Scandinavian Med Sci Sports

View full text Add to dashboard Cite

Internet websites offering androgenic anabolic steroids (AAS) were identified and available products were examined. Keywords for the website search were: "anabolic steroids," "anabolic steroids buy," "anabolic steroid purchase." The first 10 websites offering AAS in the first 10 pages of results were considered. At least two AAS-containing products per website were selected. Thirty AAS-selling websites were identified, mainly located in the United States (46.7%) and Europe (30%). Most websites sold other anabolic/ergogenic products (clenbuterol, 76.7%; GH/IGF, 60.0%; thyroid hormones, 46.7%; erythropoietin, 30.0%; insulin, 20.0%) or products for AAS-related adverse effects (mainly: estrogen antagonists, 63.3%; products for erectile dysfunction, 56.7%; 5α-reductase inhibitors, 33.3%; anti-acne products, 33.3%). AAS were sold as medicines (69.6%) or as dietary supplements (30.4%). AAS in medicines were mainly: nandronole (20.4%), methandrostenolone (18.4%), and testosterone (12.2%). Dietary supplements contained mainly DHEA and included several fake compounds. Manufacturers were declared for 97.9% of medicines and 66.7% of dietary supplements; however, several manufacturers were not found on the Internet. Described benefits were usually few adverse effects and no estrogenicity. Toxicity was seldom reported and presented as mild. Recommended doses were two-fourfold higher than current medical recommendations. In conclusion, misleading information and deceiving practices were common findings on AAS-selling websites, indicating their deleterious potential for public health.

show abstract

“…In this group, DHEA therapy has been shown to restore bone mineral density when used at doses of 100-200 mg/day, somewhat higher than the 50 mg/day used in most 'replacement' studies. 28 The US Food and Drug Administration has recently given DHEA 'orphan drug status' for the prevention of loss of bone mineral density in SLE, but has, at the same time, called for further studies into the long-term effects of DHEA.…”

Section: Bone Mineral Densitymentioning

confidence: 99%

Dehydroepiandrosterone (DHEA) and the menopause: an update

Raven

Hinson

2007

Menopause International

View full text Add to dashboard Cite

Since we last reviewed this topic in 2001, considerably more information about dehydroepiandrosterone (DHEA) has accrued, but this has not necessarily left us any wiser about the use of this steroid in postmenopausal women. There is no further evidence that DHEA supplementation is likely to be useful in the prevention of cardiovascular disease or cognitive impairment, or in the promotion of wellbeing. Evidence has, however, accumulated for beneficial effects of DHEA on osteoporosis, both in postmenopausal women and in patients receiving long-term glucocorticoid therapy. What is also emerging is a link between low DHEA levels and cardiovascular risk, and between high DHEA levels and breast cancer risk. In fact, the benefits and adverse effects of DHEA administration in postmenopausal women increasingly resemble those of conventional hormone replacement therapy. Overall, we conclude that DHEA is not currently to be recommended for therapeutic use in the majority of postmenopausal women. However, DHEA supplementation may be of benefit in two specific groups of women: those with the lowest circulating levels of DHEA; and those for whom osteoporosis is a particular problem.

show abstract

Prasterone

Abstract: FDA has granted orphan drug status for the prevention of loss of bone mineral density in SLE patients taking glucocorticoids. FDA is requesting additional Phase III trial data for the treatment of SLE and the prevention of loss of bone mineral density.

Cited by 7 publications

References 39 publications

Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians

Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians

Selling androgenic anabolic steroids by the pound: identification and analysis of popular websites on the Internet

Dehydroepiandrosterone (DHEA) and the menopause: an update

Contact Info

Product

Resources

About